Cargando…

Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients

Anti-drug antibodies can interfere with the activity of anti-tumor necrosis factor (TNF) agents by increasing drug clearance via direct neutralization. The presence of anti-drug antibodies is clinically relevant when trough drug concentrations are undetectable or sub-therapeutic. However, traditiona...

Descripción completa

Detalles Bibliográficos
Autores principales: Facchin, Sonia, Buda, Andrea, Cardin, Romilda, Agbariah, Nada, Zingone, Fabiana, De Bona, Manuela, Zaetta, Debora, Bertani, Lorenzo, Ghisa, Matteo, Barberio, Brigida, Savarino, Edoardo Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989110/
https://www.ncbi.nlm.nih.gov/pubmed/33815569
http://dx.doi.org/10.1177/1756284821999902
_version_ 1783668896125943808
author Facchin, Sonia
Buda, Andrea
Cardin, Romilda
Agbariah, Nada
Zingone, Fabiana
De Bona, Manuela
Zaetta, Debora
Bertani, Lorenzo
Ghisa, Matteo
Barberio, Brigida
Savarino, Edoardo Vincenzo
author_facet Facchin, Sonia
Buda, Andrea
Cardin, Romilda
Agbariah, Nada
Zingone, Fabiana
De Bona, Manuela
Zaetta, Debora
Bertani, Lorenzo
Ghisa, Matteo
Barberio, Brigida
Savarino, Edoardo Vincenzo
author_sort Facchin, Sonia
collection PubMed
description Anti-drug antibodies can interfere with the activity of anti-tumor necrosis factor (TNF) agents by increasing drug clearance via direct neutralization. The presence of anti-drug antibodies is clinically relevant when trough drug concentrations are undetectable or sub-therapeutic. However, traditional immunoassay is not easily and rapidly accessible, making the translation of the results into treatment adjustment difficult. The availability of a point-of-care (POC) test for therapeutic drug monitoring (TDM) might represent an important step forward for improving the management of inflammatory bowel disease (IBD) patients in clinical practice. In this pilot study, we compared the results obtained with POC tests with those obtained by enzyme-linked immunosorbent assay (ELISA) in a group of IBD patients treated with Infliximab (IFX). We showed that POC test can reliably detect presence of antibody-to-IFX with 100% of specificity and 76% sensitivity, in strong agreement with the ELISA test (k-coefficient = 0.84).
format Online
Article
Text
id pubmed-7989110
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-79891102021-04-02 Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients Facchin, Sonia Buda, Andrea Cardin, Romilda Agbariah, Nada Zingone, Fabiana De Bona, Manuela Zaetta, Debora Bertani, Lorenzo Ghisa, Matteo Barberio, Brigida Savarino, Edoardo Vincenzo Therap Adv Gastroenterol Case Series Anti-drug antibodies can interfere with the activity of anti-tumor necrosis factor (TNF) agents by increasing drug clearance via direct neutralization. The presence of anti-drug antibodies is clinically relevant when trough drug concentrations are undetectable or sub-therapeutic. However, traditional immunoassay is not easily and rapidly accessible, making the translation of the results into treatment adjustment difficult. The availability of a point-of-care (POC) test for therapeutic drug monitoring (TDM) might represent an important step forward for improving the management of inflammatory bowel disease (IBD) patients in clinical practice. In this pilot study, we compared the results obtained with POC tests with those obtained by enzyme-linked immunosorbent assay (ELISA) in a group of IBD patients treated with Infliximab (IFX). We showed that POC test can reliably detect presence of antibody-to-IFX with 100% of specificity and 76% sensitivity, in strong agreement with the ELISA test (k-coefficient = 0.84). SAGE Publications 2021-03-21 /pmc/articles/PMC7989110/ /pubmed/33815569 http://dx.doi.org/10.1177/1756284821999902 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Series
Facchin, Sonia
Buda, Andrea
Cardin, Romilda
Agbariah, Nada
Zingone, Fabiana
De Bona, Manuela
Zaetta, Debora
Bertani, Lorenzo
Ghisa, Matteo
Barberio, Brigida
Savarino, Edoardo Vincenzo
Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients
title Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients
title_full Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients
title_fullStr Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients
title_full_unstemmed Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients
title_short Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients
title_sort rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with elisa and potential for improving therapeutic drug monitoring in ibd patients
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989110/
https://www.ncbi.nlm.nih.gov/pubmed/33815569
http://dx.doi.org/10.1177/1756284821999902
work_keys_str_mv AT facchinsonia rapidpointofcareantiinfliximabantibodiesdetectioninclinicalpracticecomparisonwithelisaandpotentialforimprovingtherapeuticdrugmonitoringinibdpatients
AT budaandrea rapidpointofcareantiinfliximabantibodiesdetectioninclinicalpracticecomparisonwithelisaandpotentialforimprovingtherapeuticdrugmonitoringinibdpatients
AT cardinromilda rapidpointofcareantiinfliximabantibodiesdetectioninclinicalpracticecomparisonwithelisaandpotentialforimprovingtherapeuticdrugmonitoringinibdpatients
AT agbariahnada rapidpointofcareantiinfliximabantibodiesdetectioninclinicalpracticecomparisonwithelisaandpotentialforimprovingtherapeuticdrugmonitoringinibdpatients
AT zingonefabiana rapidpointofcareantiinfliximabantibodiesdetectioninclinicalpracticecomparisonwithelisaandpotentialforimprovingtherapeuticdrugmonitoringinibdpatients
AT debonamanuela rapidpointofcareantiinfliximabantibodiesdetectioninclinicalpracticecomparisonwithelisaandpotentialforimprovingtherapeuticdrugmonitoringinibdpatients
AT zaettadebora rapidpointofcareantiinfliximabantibodiesdetectioninclinicalpracticecomparisonwithelisaandpotentialforimprovingtherapeuticdrugmonitoringinibdpatients
AT bertanilorenzo rapidpointofcareantiinfliximabantibodiesdetectioninclinicalpracticecomparisonwithelisaandpotentialforimprovingtherapeuticdrugmonitoringinibdpatients
AT ghisamatteo rapidpointofcareantiinfliximabantibodiesdetectioninclinicalpracticecomparisonwithelisaandpotentialforimprovingtherapeuticdrugmonitoringinibdpatients
AT barberiobrigida rapidpointofcareantiinfliximabantibodiesdetectioninclinicalpracticecomparisonwithelisaandpotentialforimprovingtherapeuticdrugmonitoringinibdpatients
AT savarinoedoardovincenzo rapidpointofcareantiinfliximabantibodiesdetectioninclinicalpracticecomparisonwithelisaandpotentialforimprovingtherapeuticdrugmonitoringinibdpatients